|
1
|
Pancione M, Remo A and Colantuoni V:
Genetic and epigenetic events generate multiple pathways in
colorectal cancer progression. Pathol Res Int. 2012:5093482012.
View Article : Google Scholar
|
|
2
|
Ewing I, Hurley JJ, Josephides E and
Millar A: The molecular genetics of colorectal cancer. Frontline
Gastroenterol. 5:26–30. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vogelstein B, Fearon ER, Hamilton SR, Kern
SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos
JL: Genetic alterations during colorectal-tumor development. N Engl
J Med. 319:525–532. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Burt RW: Colon cancer screening.
Gastroenterology. 119:837–853. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jasperson KW, Tuohy TM, Neklason DW and
Burt RW: Hereditary and familial colon cancer. Gastroenterology.
138:2044–2058. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Duraturo F, Liccardo R, Cavallo A, De Rosa
M, Grosso M and Izzo P: Association of low-risk MSH3 and MSH2
variant alleles with Lynch syndrome: Probability of synergistic
effects. Int J Cancer. 129:1643–1650. 2011. View Article : Google Scholar
|
|
7
|
Rustgi AK: The genetics of hereditary
colon cancer (Review). Genes Dev. 21:2525–2538. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Peifer M: Developmental biology: colon
construction. Nature. 420:274–275. 2772002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kosinski C, Li Vs, Chan AS, Zhang J, Ho C,
Tsui WY, Chan TL, Mifflin RC, Powell DW, Yuen ST, et al: Gene
expression patterns of human colon tops and basal crypts and BMP
antagonists as intestinal stem cell niche factors. Proc Natl Acad
Sci USA. 104:15418–15423. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Medema JP and Vermeulen L:
Microenvironmental regulation of stem cells in intestinal
homeostasis and cancer (Review). Nature. 474:318–326. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goel A, Nagasaka T, Arnold CN, Inoue T,
Hamilton C, Niedzwiecki D, Compton C, Mayer RJ, Goldberg R,
Bertagnolli MM, et al: The CPG island methylator phenotype and
chromosomal instability are inversely correlated in sporadic
colorectal cancer. Gastroenterology. 132:127–138. 2007. View Article : Google Scholar
|
|
12
|
Sideris M and Papagrigoriadis S: Molecular
biomarkers and classification models in the evaluation of the
prognosis of colorectal cancer (Review). Anticancer Res.
34:2061–2068. 2014.PubMed/NCBI
|
|
13
|
Pino MS and Chung DC: The chromosomal
instability pathway in colon cancer. Gastroenterology.
138:2059–2072. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Boland CR and Goel A: Microsatellite
instability in colorectal cancer (Review). Gastroenterology.
138:2073–2087.e3. 2010. View Article : Google Scholar
|
|
15
|
Colussi D, Brandi G, Bazzoli F and
Ricciardiello L: Molecular pathways involved in colorectal cancer:
implications for disease behavior and prevention. Int J Mol Sci.
14:16365–16385. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Markowitz SD and Bertagnolli MM: Molecular
Origins of cancer: molecular basis of colorectal cancer. N Engl J
Med. 361:2449–2460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Najdi R, Holcombe RF and Waterman ML: Wnt
signaling and colon carcinogenesis: beyond APC. J Carcinog.
10:52011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
MacDonald BT, Tamai K and He X:
Wnt/β-catenin signaling: components, mechanisms and diseases. Dev
Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Polakis P: Wnt signaling and cancer. Genes
Dev. 14:1837–51. 2000.PubMed/NCBI
|
|
20
|
Giles RH, van Es JH and Clevers H: Caught
up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta.
1653:1–24. 2003.PubMed/NCBI
|
|
21
|
Dejana E: The role of wnt signaling in
physiological and pathological angiogenesis. Circ Res. 107:943–952.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Planutis K, Planutiene M and Holcombe RF:
A novel signaling pathway regulates colon cancer angiogenesis
through Norrin. Sci Rep. 4:56302014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shaw RJ and Cantley LC: Ras, PI(3)K and
mTOR signalling controls tumour cell growth. Nature. 441:424–430.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fresno Vara JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Testa JR and Bellacosa A: AKT plays a
central role in tumorigenesis. Proc Natl Acad Sci USA.
98:10983–10985. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Martini M, De Santis MC, Braccini I,
Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: an
updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Porta C, Paglino C and Mosca A: Targeting
PI3K/Akt/mTOR signaling in cancer. Front Oncol. 4:642014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee G, Goretsky T, Managlia E, Dirisina R,
Singh AP, Brown JB, May R, Yang GY, Ragheb JW, Evers BM, et al:
Phosphoinositide 3-kinase signaling mediates β-catenin activation
in intestinal epithelial stem and progenitor cells in colitis.
Gastroenterology. 139:869–881. 2010. View Article : Google Scholar
|
|
29
|
Simpson L and Parsons R: PTEN: life as a
tumor suppressor. Exp Cell Res. 264:29–41. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Salmena L, Carracedo A and Pandolf PP:
Tenets of PTEN tumor suppression. Cell. 133:403–414. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Manfredi M: Hereditary hamartomatous
polyposis syndromes: understanding the disease risks as children
reach adulthood. Gastroenterol Hepatol (NY). 6:185–196. 2010.
|
|
32
|
Eng C: PTEN: one gene, many syndromes. Hum
Mutat. 22:183–198. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Galatola M, Paparo I, Duraturo F, Turano
M, Rossi GB, Izzo P and De Rosa M: Β catenin and cytokine pathway
dysregulation in patients with manifestations of the 'PTEN
hamartoma tumor syndrome'. BMC Med Genet. 13:282012. View Article : Google Scholar
|
|
34
|
Alimonti A, Carracedo A, Clohessy JG,
Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ,
Brogi E, et al: Subtle variations in Pten dose determine cancer
susceptibility. Nat Genet. 42:454–458. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Paparo I, Rossi GB, Delrio P, Rega D,
Duraturo F, Liccardo R, Debellis M, Izzo P and De Rosa M:
Differential expression of PTEN gene correlates with phenotypic
heterogeneity in three cases of patients showing clinical
manifestations of PTEN hamartoma tumour syndrome. Hered Cancer Clin
Pract. 11:82013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Malumbres M and Barbacid M: RAS oncogenes:
the first 30 years. Nat Rev Cancer. 3:459–465. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Scaltriti M and Baselga J: The epidermal
growth factor receptor pathway: a model for targeted therapy. Clin
Cancer Res. 12:5268–5272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hallberg B, Rayter SI and Downward J:
Interaction of Ras and Raf in intact mammalian cells upon
extracellular stimulation. J Biol Chem. 269:3913–3916.
1994.PubMed/NCBI
|
|
39
|
Liebmann C: Regulation of MAP kinase
activity by peptide receptor signalling pathway: paradigms of
multiplicity. Cell Signal. 13:777–785. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Shao DD, Xue W, Krall EB, Bhutkar A,
Piccioni F, Wang X, Schinzel AC, Sood S, Rosenbluh J, Kim JW, et
al: KRAS and YAP1 converge to regulate EMT and tumor survival.
Cell. 158:171–184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen F and Castranova V: Nuclear
factor-kappaB, an unappreciated tumor suppressor. Cancer Res.
67:11093–11098. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Perkins ND: NF-κB: tumor promoter or
suppressor? Trends Cell Biol. 14:64–69. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Du Q and Geller DA: Cross-regulation
between Wnt and NF-κB signaling pathways. For Immunopathol. Dis
Therap. 1:155–181. 2010.
|
|
44
|
Hoesel B and Schmid JA: The complexity of
NF-κB signaling in inflammation and cancer. Mol Cancer. 12:1–15.
2013. View Article : Google Scholar
|
|
45
|
Mccubrey JA, Steelman LS, Bertrand FE,
Davis NM, Sokolosky M, Abrams SL, Montalto G, D'Assoro AB, Libra M,
Nicoletti F, et al: GSK-3 as potential target for therapeutic
intervention in cancer. Oncotarget. 5:2881–2911. 2014.PubMed/NCBI
|
|
46
|
Li H, Huang K, Liu X, Liu J, Lu X, Tao K,
Wang G and Wang J: Lithium chloride suppresses colorectal cancer
cell survival and proliferation through ROS/GSK-3β/NF-κb signaling
pathway. Oxid Med Cell Longev. 2014:2418642014. View Article : Google Scholar
|
|
47
|
Mishra R: Glycogen synthase kinase 3β: can
it be a target for oral cancer. Mol Cancer. 9:1442010. View Article : Google Scholar
|
|
48
|
Loboda A, Nebozhyn MV, Watters JW, Buser
CA, Shaw PM, Huang PS, Van't Veer L, Tollenaar RA, Jackson DB,
Agrawal D, et al: EMT is the dominant program in human colon
cancer. BMC Med Genomics. 4:92011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Batlle E, Sancho E, Francí C, Domínguez D,
Monfar M, Baulida J and García De Herreros A: The transcription
factor Snail is a repressor of E-cadherin gene expression in
epithelial tumour cells. Nat Cell Biol. 2:84–89. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cano A, Pérez-Moreno MA, Rodrigo I,
Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The
transcription factor Snail controls epithelial-mesenchymal
transitions by repressing E-cadherin expression. Nat Cell Biol.
2:76–83. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Li X, Pei D, Zheng H and Li X1:
Transitions between epithelial and mesenchymal states during cell
fate conversions. Protein Cell. 5:580–591. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Giannelli G, Villa E and Lahn M:
Transforming growth factor-β as a therapeutic target in
hepatocellular carcinoma. Cancer Res. 74:1890–1894. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Costabile V, Duraturo F, Delrio P, Rega D,
Pace U, Liccardo R, Rossi GB, Genesio R, Nitsch L, Izzo P, et al:
Lithium chloride induces mesenchymal to epithelial reverting
transition in primary colon cancer cell cultures. Int J Oncol.
46:1913–1923. 2015.PubMed/NCBI
|
|
56
|
Jasperson KW, Tuohy TM, Neklason DW and
Burt RW: Hereditary and familial colon cancer. Gastroenterology.
138:2044–2058. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Gallagher DJ, Smith JD, Offit K and
stadler ZK: Diagnosing hereditary colorectal cancer. Clin
Colorectal Cancer. 9:205–211. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lucci-Cordisco E, Risio M, Venesio T and
Genuardi M: The growing complexity of the intestinal polyposis
syndromes. Am J Med Genet A. 161A:2777–2787. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
De Rosa M, Duraturo F, Liccardo R and Izzo
P: Hereditary gastrointestinal polyposis: diagnosis, genetic test
and risk assessment. Open J Genet. 3:50–58. 2013. View Article : Google Scholar
|
|
60
|
Kolfschoten NE, Wouters MW, Gooiker GA,
Eddes EH, Kievit J, Tollenaar RA and Marang-van de Mheen PJ: Dutch
surgical colorectal audit group: nonelective colon cancer
resections in elderly patients: results from the dutch surgical
colorectal audit. Dig Surg. 29:412–419. 2012. View Article : Google Scholar
|
|
61
|
Smothers L, Hynan L, Fleming J, Turnage R,
Simmang C and Anthony T: Emergency surgery for colon carcinoma. Dis
Colon Rectum. 46:24–30. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kekelidze M, D'Errico L, Pansini M,
Tyndall A and Hohmann J: Colorectal cancer: current imaging methods
and future perspectives for the diagnosis, staging and therapeutic
response evaluation. World J Gastroenterol. 19:8502–8514. 2013.
View Article : Google Scholar :
|
|
63
|
Leufkens AM, van den Bosch MA, van Leeuwen
MS and Siersema PD: Diagnostic accuracy of computed tomography for
colon cancer staging: a systematic review. Scand J Gastroenterol.
46:887–894. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Mitry E, Guiu B, Cosconea S, Jooste V,
Faivre J and Bouvier AM: Epidemiology, management and prognosis of
colorectal cancer with lung metastases: a 30-year population-based
study. Gut. 59:1383–1388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Barret M, Boustiere C, Canard JM, Arpurt
JP, Bernardini D, Bulois P, Chaussade S, Heresbach D, Joly I,
Lapuelle J, et al: Société Française d'endoscopie Digestive:
factors associated with adenoma detection rate and diagnosis of
polyps and colorectal cancer during colonoscopy in France: results
of a prospective, nationwide survey. PLoS One. 8:e689472013.
View Article : Google Scholar
|
|
66
|
Kaminski MF, Regula J, Kraszewska E,
Polkowski M, Wojciechowska U, Didkowska J, Zwierko M, Rupinski M,
Nowacki MP and Butruk E: Quality indicators for colonoscopy and the
risk of interval cancer. N Engl J Med. 362:1795–1803. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zauber AG, Winawer SJ, O'Brien MJ,
Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, Shi W, Bond JH,
Schapiro M, Panish JF, et al: Colonoscopic polypectomy and
long-term prevention of colorectal-cancer deaths. N Engl J Med.
366:687–696. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Graser A, Stieber P, Nagel D, Schäfer C,
Horst D, Becker CR, Nikolaou K, Lottes A, Geisbüsch S, Kramer H, et
al: Comparison of CT colonography, colonoscopy, sigmoidoscopy and
faecal occult blood tests for the detection of advanced adenoma in
an average risk population. Gut. 58:241–248. 2009. View Article : Google Scholar
|
|
69
|
Pickhardt PJ, Hassan C, Halligan S and
Marmo R: Colorectal cancer: CT colonography and colonoscopy for
detection - systematic review and meta-analysis. Radiology.
259:393–405. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Pullens HJ, van Leeuwen MS, Laheij RJ,
Vleggaar FP and Siersema PD: CT-colonography after incomplete
colonoscopy: What is the diagnostic yield? Dis Colon Rectum.
56:593–599. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Atkin W, Dadswell E, Wooldrage K,
Kralj-Hans I, von Wagner C, Edwards R, Yao G, Kay C, Burling D,
Faiz O, et al: SIGGAR investigators: computed tomographic
colonography versus colonoscopy for investigation of patients with
symptoms suggestive of colorectal cancer (SIGGAR): a multicentre
randomised trial. Lancet. 381:1194–1202. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Edge SB and Compton CC: The American Joint
Committee on cancer: the 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Bipat S, Niekel MC, Comans EF, Nio CY,
Bemelman WA, Verhoef C and Stoker J: Imaging modalities for the
staging of patients with colorectal cancer. Neth J Med. 70:26–34.
2012.PubMed/NCBI
|
|
74
|
Floriani I, Torri V, Rulli E, Garavaglia
D, Compagnoni A, Salvolini L and Giovagnoni A: Performance of
imaging modalities in diagnosis of liver metastases from colorectal
cancer: a systematic review and meta-analysis. J Magn Reson
Imaging. 31:19–31. 2010. View Article : Google Scholar
|
|
75
|
Niekel MC, Bipat S and Stoker J:
Diagnostic imaging of colorectal liver metastases with CT, MR
imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective
studies including patients who have not previously undergone
treatment. Radiology. 257:674–684. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Dighe S, Blake H, Koh MD, Swift I, Arnaout
A, Temple L, Barbachano Y and Brown G: Accuracy of multidetector
computed tomography in identifying poor prognostic factors in
colonic cancer. Br J Surg. 97:1407–1415. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Dighe S, Purkayastha S, Swift I, Tekkis
PP, Darzi A, A'Hern R and Brown G: Diagnostic precision of CT in
local staging of colon cancers: A meta-analysis. Clin Radiol.
65:708–719. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Schmoll HJ, Van Cutsem E, Stein A,
Valentini V, Glimelius B, Haustermans K, Nordlinger B, Van de Velde
CJ, Balmana J, Regula J, et al: ESMO consensus guidelines for
management of patients with colon and rectal cancer. A personalized
approach to clinical decision making. Ann Oncol. 23:2479–2516.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Glimelius B, Beets-Tan R, Blomqvist L,
Brown G, Nagtegaal I, Påhlman L, Quirke P, Valentini V and van de
Velde C: Mesorectal fascia instead of circumferential resection
margin in preoperative staging of rectal cancer. J Clin Oncol.
29:2142–2143. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Van de Velde CJ, Aristei C, Boelens PG,
Beets-Tan RG, Blomqvist L, Borras JM, van den Broek CB, Brown G,
Coebergh JW, Cutsem EV, et al: European registration of cancer
care: EURECCA colorectal: multidisciplinary mission statement on
better care for patients with colon and rectal cancer in Europe.
Eur J Cancer. 49:2784–2790. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Torkzad MR, Påhlman L and Glimelius B:
Magnetic resonance imaging (MRI) in rectal cancer: a comprehensive
review. Insights Imaging. 1:245–267. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Poston GJ, Tait D, O'Connell S, Bennett A
and Berendse S: Guideline development group: diagnosis and
management of colorectal cancer: summary of NICE guidance. BMJ.
343:d67512011. View Article : Google Scholar
|
|
83
|
Swartling T, Kälebo P, Derwinger K,
Gustavsson B and Kurlberg G: Stage and size using magnetic
resonance imaging and endosonography in neoadjuvantly-treated
rectal cancer. World J Gastroenterol. 19:3263–3271. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Hohenberger W, Weber K, Matzel K,
Papadopoulos T and Merkel S: Standardized surgery for colonic
cancer: complete mesocolic excision and central ligation -
technical notes and outcome. Colorectal Dis. 11:354–364; discussion
364–365. 2009. View Article : Google Scholar
|
|
85
|
Sehgal R and Coffey JC: Historical
development of mesenteric anatomy provides a universally applicable
anatomic paradigm for complete/total mesocolic excision.
Gastroenterol Rep (Oxf). 2:245–250. 2014. View Article : Google Scholar
|
|
86
|
Søndenaa K, Quirke P, Hohenberger W,
Sugihara K, Kobayashi H, Kessler H, Brown G, Tudyka V, D'Hoore A,
Kennedy RH, et al: The rationale behind complete mesocolic excision
(CME) and a central vascular ligation for colon cancer in open and
laparoscopic surgery: proceedings of a consensus conference. Int J
Colorectal Dis. 29:419–428. 2014. View Article : Google Scholar
|
|
87
|
Siani LM and Pulica C: Stage I-IIIC right
colonic cancer treated with complete mesocolic excision and central
vascular ligation: quality of surgical specimen and long term
oncologic outcome according to the plane of surgery. Minerva Chir.
69:199–208. 2014.PubMed/NCBI
|
|
88
|
Sagar J: Colorectal stents for the
management of malignant colonic obstructions. Cochrane Database
Syst Rev. 11:CD0073782011.Review. PubMed/NCBI
|
|
89
|
Fuccio L, Cennamo V and de Bellis M: Risk
factors for stent-related adverse events in patients with
obstructive colorectal cancer: are we missing something?
Gastrointest Endosc. 80:742–743. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Fuccio L, Correale L, Arezzo A, Repici A,
Manes G, Trovato C, Mangiavillano B, Manno M, Cortelezzi CC,
Dinelli M, et al: KRASTENT Study Group: influence of K-ras status
and anti-tumour treatments on complications due to colorectal
self-expandable metallic stents: a retrospective multicentre study.
Dig Liver Dis. 46:561–567. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Yang TX and Chua TC: Single-incision
laparoscopic colectomy versus conventional multiport laparoscopic
colectomy: a meta-analysis of comparative studies. Int J Colorectal
Dis. 28:89–101. 2013. View Article : Google Scholar
|
|
92
|
Mynster T, Hammer J and Wille-Jørgensen P:
Preliminary results after single-port laparoscopic colonic surgery.
Dan Med J. 59:A45512012.
|
|
93
|
Huscher CG, Mingoli A, Sgarzini G, Mereu
A, Binda B, Brachini G and Trombetta S: Standard laparoscopic
versus single-incision laparoscopic colectomy for cancer: early
results of a randomized prospective study. Am J Surg. 204:115–120.
2012. View Article : Google Scholar
|
|
94
|
Wolthuis AM, Penninckx F, Fieuws S and
D'Hoore A: Outcomes for case-matched single-port colectomy are
comparable with conventional laparoscopic colectomy. Colorectal
Dis. 14:634–641. 2012. View Article : Google Scholar
|
|
95
|
Ramos-Valadez DI, Ragupathi M, Nieto J,
Patel CB, Miller S, Pickron TB and Haas EM: Single-incision versus
conventional laparoscopic sigmoid colectomy: a case-matched series.
Surg Endosc. 26:96–102. 2012. View Article : Google Scholar
|
|
96
|
Tyler JA, Fox JP, Desai MM, Perry WB and
Glasgow SC: Outcomes and costs associated with robotic colectomy in
the minimally invasive era. Dis Colon Rectum. 56:458–466. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Baek SK, Carmichael JC and Pigazzi A:
Robotic surgery: colon and rectum. Cancer J. 19:140–146. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Glimelius B, Beets-Tan R, Blomqvist L,
Brown G, Nagtegaal I, Påhlman L, Quirke P, Valentini V and van de
Velde C: Mesorectal fascia instead of circumferential resection
margin in preoperative staging of rectal cancer. J Clin Oncol.
29:2142–2143. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Sgourakis G, Lanitis S, Gockel I,
Kontovounisios C, Karaliotas C, Tsiftsi K, Tsiamis A and Karaliotas
CC: Transanal endoscopic microsurgery for T1 and T2 rectal cancers:
a meta-analysis and meta-regression analysis of outcomes. Am Surg.
77:761–772. 2011.PubMed/NCBI
|
|
100
|
Guerrieri M, Gesuita R, Ghiselli R,
Lezoche G, Budassi A and Baldarelli M: Treatment of rectal cancer
by transanal endoscopic microsurgery: experience with 425 patients.
World J Gastroenterol. 20:9556–9563. 2014.PubMed/NCBI
|
|
101
|
Matz J and Matz A: Use of a SILS port in
transanal endoscopic microsurgery in the setting of a community
hospital. J Laparoendosc Adv Surg Tech A. 22:93–96. 2012.
View Article : Google Scholar
|
|
102
|
Atallah S, Albert M and Larach S:
Transanal minimally invasive surgery: a giant leap forward. Surg
Endosc. 24:2200–2205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Guillou PJ, Quirke P, Thorpe H, Walker J,
Jayne DG, Smith AM, Heath RM and Brown JM: MRC CLASICC trial group:
short-term endpoints of conventional versus laparoscopic-assisted
surgery in patients with colorectal cancer (MRC CLASICC trial):
multicentre, randomised controlled trial. Lancet. 365:1718–1726.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Jayne DG, Thorpe HC, Copeland J, Quirke P,
Brown JM and Guillou PJ: Five-year follow-up of the Medical
Research Council CLASICC trial of laparoscopically assisted versus
open surgery for colorectal cancer. Br J Surg. 97:1638–1645. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Kang SB, Park JW, Jeong SY, Nam BH, Choi
HS, Kim DW, Lim SB, Lee TG, Kim DY, Kim JS, et al: Open versus
laparoscopic surgery for mid or low rectal cancer after neoadjuvant
chemoradiotherapy (COREAN trial): short-term outcomes of an
open-label randomised controlled trial. Lancet Oncol. 11:637–645.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
van der Pas MH, Haglind E, Cuesta MA,
Fürst A, Lacy AM, Hop WC and Bonjer HJ: Colorectal cancer
laparoscopic or open resection II (COLOR II) study group:
laparoscopic versus open surgery for rectal cancer (COLOR II):
short-term outcomes of a randomised, phase 3 trial. Lancet Oncol.
14:210–218. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Yang Y, Wang F, Zhang P, Shi C, Zou Y, Qin
H and Ma Y: Robot-assisted versus conventional laparoscopic surgery
for colorectal disease, focusing on rectal cancer: a meta-analysis.
Ann Surg Oncol. 19:3727–3736. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Lin S, Jiang HG, Chen ZH, Zhou SY, Liu XS
and Yu JR: Meta-analysis of robotic and laparoscopic surgery for
treatment of rectal cancer. World J Gastroenterol. 17:5214–5220.
2011. View Article : Google Scholar
|
|
109
|
Park JS, Choi GS, Lim KH, Jang YS and Jun
SH: S052: a comparison of robot-assisted, laparoscopic, and open
surgery in the treatment of rectal cancer. Surg Endosc. 25:240–248.
2011. View Article : Google Scholar
|
|
110
|
Kim JC, Yang SS, Jang TY, Kwak JY, Yun MJ
and Lim SB: Open versus robot-assisted sphincter-saving operations
in rectal cancer patients: techniques and comparison of outcomes
between groups of 100 matched patients. Int J Med Robot. 8:468–475.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Kim JY, Kim N-K, Lee KY, Hur H, Min BS and
Kim JH: A comparative study of voiding and sexual function after
total mesorectal excision with autonomic nerve preservation for
rectal cancer: laparoscopic versus robotic surgery. Ann Surg Oncol.
19:2485–2493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
D'Annibale A, Pernazza G, Monsellato I,
Pende V, Lucandri G, Mazzocchi P and Alfano G: Total mesorectal
excision: a comparison of oncological and functional outcomes
between robotic and laparoscopic surgery for rectal cancer. Surg
Endosc. 27:1887–1895. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Luca F, Valvo M, Ghezzi TL, Auccaro M,
Cenciarelli S, Trovato C, Sonzogni A and Biffi R: Impact of robotic
surgery on sexual and urinary functions after fully robotic
nerve-sparing total mesorectal excision for rectal cancer. Ann
Surg. 257:672–678. 2013. View Article : Google Scholar
|
|
114
|
Collinson FJ, Jayne DG, Pigazzi A, Tsang
C, Barrie JM, Edlin R, Garbett C, Guillou P, Holloway I, Howard H,
et al: An international, multicentre, prospective, randomised,
controlled, unblinded, parallel-group trial of robotic-assisted
versus standard laparoscopic surgery for the curative treatment of
rectal cancer. Int J Colorectal Dis. 27:233–241. 2012. View Article : Google Scholar
|
|
115
|
Memon S, Heriot AG, Murphy DG, Bressel M
and Lynch AC: Robotic versus laparoscopic proctectomy for rectal
cancer: a meta-analysis. Ann Surg Oncol. 19:2095–2101. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Trastulli S, Farinella E, Cirocchi R,
Cavaliere D, Avenia N, Siannameo F, Gullà N, Noya G and Boselli C:
Robotic resection compared with laparoscopic rectal resection for
cancer: systematic review and meta-analysis of short-term outcome.
Colorectal Dis. 14:e134–e156. 2012. View Article : Google Scholar
|
|
117
|
Valentini V, Aristei C, Glimelius B,
Minsky BD, Beets-Tan R, Borras JM, Haustermans K, Maingon P,
Overgaard J, Pahlman L, et al: Scientific committee:
multidisciplinary rectal cancer management: 2nd European rectal
cancer consensus conference (EURECA-CC2). Radiother Oncol.
92:148–163. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Sauer R, Liersch T, Merkel S, Fietkau R,
Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Witzigmann
H, et al: Preoperative versus postoperative chemoradiotherapy for
locally advanced rectal cancer: results of the German
CAO/ARO/AIO-94 randomized phase III trial after a median follow-up
of 11 years. J Clin Oncol. 30:1926–1933. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Schmoll HJ, Van Cutsem E, Stein A,
Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde
CJ, Balmana J, Regula J, et al: ESMO Consensus Guidelines for
management of patients with colon and rectal cancer. A personalized
approach to clinical decision making. Ann Oncol. 23:2479–2516.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Pettersson D, Glimelius B, Iversen H,
Johansson H, Holm T and Martling A: Impaired postoperative
leucocyte counts after preoperative radiotherapy for rectal cancer
in the Stockholm III trial. Br J Surg. 100:969–975. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Pettersson D, Cedermark B, Holm T, Radu C,
Påhlman L, Glimelius B and Martling A: Interim analysis of the
Stockholm III trial of preoperative radiotherapy regimens for
rectal cancer. Br J Surg. 97:580–587. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Bujko K, Nowacki MP, Nasierowska-Guttmejer
A, Michalski W, Bebenek M and Kryj M: Long-term results of a
randomized trial comparing preoperative short-course radiotherapy
with preoperative conventionally fractionated chemoradiation for
rectal cancer. Br J Surg. 93:1215–1223. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Ngan SY, Burmeister B, Fisher RJ, Solomon
M, Goldstein D, Joseph D, Ackland SP, Schache D, Mcclure B,
Mclachlan SA, et al: Randomized trial of short-course radiotherapy
versus long-course chemoradiation comparing rates of local
recurrence in patients with T3 rectal cancer: trans-tasman
radiation oncology group trial 01.04. J Clin Oncol. 30:3827–3833.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Siegel R, Burock S, Wernecke KD,
Kretzschmar A, Dietel M, Loy V, Koswig S, budach V and Schlag PM:
Preoperative short-course radiotherapy versus combined
radiochemotherapy in locally advanced rectal cancer: a multi-centre
prospectively randomised study of the Berlin Cancer Society. BMC
Cancer. 9:502009. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Hofheinz RD, Wenz F, Post S, Matzdorff A,
Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, et
al: Chemoradiotherapy with capecitabine versus fluorouracil for
locally advanced rectal cancer: a randomised, multicentre,
non-inferiority, phase 3 trial. Lancet Oncol. 13:579–588. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Avallone A, Delrio P, Pecori B, Tatangelo
F, Petrillo A, Scott N, Marone P, Aloi L, Sandomenico C, Lastoria
S, et al: Oxaliplatin plus dual inhibition of thymidilate synthase
during preoperative pelvic radiotherapy for locally advanced rectal
carcinoma: long-term outcome. Int J Radiat Oncol Biol Phys.
79:670–676. 2011. View Article : Google Scholar
|
|
127
|
Gunderson LL, Jessup JM, Sargent DJ,
Greene FL and Stewart AK: Revised TN categorization for colon
cancer based on national survival outcomes data. J Clin Oncol.
28:264–271. 2010. View Article : Google Scholar :
|
|
128
|
Bombard Y, Bach PB and Offit K:
Translating genomics in cancer care. J Natl Compr Canc Netw.
11:1343–1353. 2013.PubMed/NCBI
|
|
129
|
Ross JS and Cronin M: Whole cancer genome
sequencing by next-generation methods. Am J Clin Pathol.
136:527–539. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Ribic CM, Sargent DJ, Moore MJ, Thibodeau
SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R,
Shepherd LE, et al: Tumor microsatellite-instability status as a
predictor of benefit from fluorouracil-based adjuvant chemotherapy
for colon cancer. N Engl J Med. 349:247–257. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Bertagnolli MM, Niedzwiecki D, Compton CC,
Hahn HP, Hall M, Damas B, Jewell SD, Mayer RJ, Goldberg RM, Saltz
LB, et al: Microsatellite instability predicts improved response to
adjuvant therapy with irinotecan, fluorouracil, and leucovorin in
stage III colon cancer: cancer and leukemia group B protocol 89803.
J Clin Oncol. 27:1814–1821. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Des Guetz G, Schischmanoff O, Nicolas P,
Perret GY, Morere JF and B: Does microsatellite instability predict
the efficacy of adjuvant chemotherapy in colorectal cancer? A
systematic review with meta-analysis. Eur J Cancer. 45:1890–1896.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Sargent DJ, Marsoni S, Monges G, Thibodeau
SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri
V, et al: Defective mismatch repair as a predictive marker for lack
of efficacy of fluorouracil-based adjuvant therapy in colon cancer.
J Clin Oncol. 28:3219–3226. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Tveit KM, Guren T, Glimelius B, Pfeiffer
P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund
E, et al: Phase III trial of cetuximab with continuous or
intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic
FLOX) versus FLOX alone in first-line treatment of metastatic
colorectal cancer: the NORDIC-VII study. J Clin Oncol.
30:1755–1762. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Peeters M, Price TJ, Cervantes A, Sobrero
AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, et al:
Randomized phase III study of panitumumab with fluorouracil,
leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as
second-line treatment in patients with metastatic colorectal
cancer. J Clin Oncol. 28:4706–4713. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Van Cutsem E, Köhne CH, Hitre E, Zaluski
J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G,
et al: Cetuximab and chemotherapy as initial treatment for
metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Bazan V, Migliavacca M, Zanna I, Tubiolo
C, Grassi N, Latteri MA, La Farina M, Albanese I, Dardanoni G,
Salerno S, et al: Specific codon 13 K-ras mutations are predictive
of clinical outcome in colorectal cancer patients, whereas codon 12
K-ras mutations are associated with mucinous histotype. Ann Oncol.
13:1438–1446. 2002. View Article : Google Scholar : PubMed/NCBI
|
